Close Menu

NEW YORK (GenomeWeb) – New research suggests that an immune checkpoint protein called VISTA may serve as a target for future immunotherapy development in pancreatic ductal adenocarcinoma (PDAC), which is known for its poor outcomes and resistance to existing immune checkpoint therapies that target proteins such as PD-1 or CTLA4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.